Augusut 13, 2020 -- InvestorsHub NewsWire -- via 
Goldman Small Cap Research -- PAO Group, Inc. (OTC - PAOG) is an emerging cannabis and CBD company targeting growth via two tracks. The Company is in the early stages of developing a  cannabis extract-based therapy to treat various respiratory diseases and illnesses including COPD and COVID-19. PAOG also owns a growing cannabis cultivation operation focused on hemp cultivation.

Investment Higlights (Summary)

Via its recent acquisitions, PAOG has re-positioned itself as an emerging CBD Biopharma company on a development path to treat two major respiratory diseases that each represent billions in potential market sizes. PAOG also acquired a cannabis cultivation operation generating $300,000 in annual revenue.

Leveraging a series of favorable studies, the Company is set to engage a CRO to initiate the process for potential FDA approval of RespRx, its new flagship COPD treatment. COPD represents an estimated $14.1B market by 2025.  

After completing a recent 25 patient study using RespRx to treat COVID-19 symptoms, PAOG is preparing to commence a similar development pathway for this disease. Management expects to soon file a CTAP (Coronavirus Treatment Acceleration Program) application and given the current pandemic, it is likely to be fast-tracked. 

Next Steps (Summary)

We should note that a number of CBD Biopharma companies are publicly traded, with market caps ranging as high as $100M or more. Based on our cursory due diligence we found one firm, Avianna (OTC – AVCNF – NR), which is also targeting the COVID-19 arena, that has a current market cap of around $27M. Perhaps as PAOG moves along the development path on either the COPD or COVID-19 track, it can trade toward this figure, assuming current financials and information are available.

Valuation and Conclustion (Summary)

As progress and milestones on the development path occur, PAOG’s shares warrant a closer look as they could serve as catalysts to drive the overall valuation higher for PAOG’s shares.

 See Full Goldman Small Cap Research Report And Disclosures


SOURCE: Goldman Small Cap Research


Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Kali (PK) Charts.
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Kali (PK) Charts.